Get the Stockscreener App
59.22
2.09%
1.215
After Hours:
59.22
Praxis Precision Medicines Inc stock is traded at $59.22, with a volume of 689.82K.
It is up +2.09% in the last 24 hours and up +36.67% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$58.01
Open:
$58.28
24h Volume:
689.82K
Relative Volume:
2.00
Market Cap:
$1.21B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-6.458
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+9.97%
1M Performance:
+36.67%
6M Performance:
-23.20%
1Y Performance:
+2.92%
1-Day Range:
$56.66
$61.03
1-Week Range:
$53.88
$61.03
52-Week Range:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
59.22 | 1.18B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
What makes Praxis Precision Medicines Inc. stock price move sharplyFast Gains With Reduced Risk - Metal.it
What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com
Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional
Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa
PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus
Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha
FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada
Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest
Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq
FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada
FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):